Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Baudax Bio Inc BXRXQ

Healthcare Biotechnology
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in... see more

Recent & Breaking News (GREY:BXRXQ)

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 3, 2020

Baudax Bio Announces Full Commercial Launch of ANJESO(TM) and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020

GlobeNewswire June 15, 2020

Baudax Bio Secures $50 Million Credit Facility

GlobeNewswire June 1, 2020

Baudax Bio Reports First Quarter 2020 Financial Results

GlobeNewswire May 8, 2020

Baudax Bio Announces Presentation of New Phase IIIb ANJESO(TM) Data at Digestive Disease Week 2020

GlobeNewswire May 5, 2020

Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters

GlobeNewswire May 1, 2020

Baudax Bio Announces Presentation of New Phase IIIb ANJESO(TM) Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

GlobeNewswire April 23, 2020

Baudax Bio Announces U.S. Availability of ANJESO(TM) (meloxicam) Injection for the Management of Moderate to Severe Pain

GlobeNewswire April 7, 2020

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 3, 2020

Baudax Bio Announces Closing of $25 Million Public Offering of Securities

GlobeNewswire March 26, 2020

Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants

GlobeNewswire March 24, 2020

Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire March 23, 2020

Baudax Bio Signs Non-Binding Term Sheet for Debt Facility

GlobeNewswire March 4, 2020

Baudax Bio Announces FDA Approval of ANJESO(TM) for the Management of Moderate to Severe Pain

GlobeNewswire February 20, 2020

Baudax Bio Reports 2019 Annual Financial Results

GlobeNewswire February 13, 2020

Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

GlobeNewswire January 22, 2020